Therefore, the phase 3, open-label, randomized trial enrolled 344 participants who were either ineligible for or declined cisplatin, assigning them to receive either surgery alone or a combination of surgery and perioperative enfortumab vedotin (EV) plus pembrolizumab (P). The results suggest that for the predominantly cisplatin-ineligible population with muscle-invasive bladder cancer, adding perioperative enfortumab vedotin and pembrolizumab to surgical resection leads to significantly improved survival and a much higher likelihood of achieving a pathological complete response. These data demonstrate that the experimental regimen effectively doubles the two-year event-free survival rate compared to the current standard of surgery alone. Thus, the study concludes that the inclusion of this perioperative combination therapy could represent a transformative shift in clinical practice for managing cisplatin-ineligible patients with bladder cancer. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.